
Aptargroup (ATR) Stock Forecast & Price Target
Aptargroup (ATR) Analyst Ratings
Bulls say
AptarGroup has demonstrated strong performance with its AMS Solutions segment, achieving approximately 10% compound annual growth rate (CAGR) and contributing about 5% to the overall revenue forecast for FY24. The company’s Injectables business is also experiencing significant growth, reflecting a 9% CAGR due to increasing demand for biologics and GLP-1s, which is expected to drive further margin expansion. With the Pharma segment accounting for more than two-thirds of AptarGroup's profits, the continued advancements in both AMS Solutions and Injectables present a solid foundation for the company's financial outlook.
Bears say
AptarGroup faces significant risks that could hinder its financial performance, particularly its transition to a majority Pharma focus, which may take longer than anticipated, thereby limiting growth potential and margin expansion. The company’s global operations expose it to various currency and country risks, compounded by the potential impact of economic cycles on industry demand. Additionally, challenges such as regulatory inspections, trade tensions, and the inability to protect intellectual property may further undermine its competitive advantages and revenue stability.
This aggregate rating is based on analysts' research of Aptargroup and is not a guaranteed prediction by Public.com or investment advice.
Aptargroup (ATR) Analyst Forecast & Price Prediction
Start investing in Aptargroup (ATR)
Order type
Buy in
Order amount
Est. shares
0 shares